Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 0.0% | | | | | | |
| Research and development | 7.6 | 6.5 | 4.1 | 2.0 | 1.8 | 0.9 | 0.3 |
| General and administrative | 2.9 | 2.6 | 2.4 | 2.4 | 1.6 | 1.2 | 0.9 |
| EBIT | -10.5 | -9.1 | -6.5 | -4.3 | -3.3 | -2.1 | -1.2 |
| EBIT margin | -12659.3% | | | | | | |
| Pre-tax income | -10.5 | -9.1 | -6.3 | -4.2 | -3.2 | -16.6 | -1.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | |
| Net income | -10.5 | -9.1 | -6.3 | -4.2 | -3.2 | -16.6 | -1.2 |
| Net margin | -12633.8% | | | | | | |
| |
| Diluted EPS | ($0.83) | ($0.73) | ($0.58) | ($0.45) | ($0.35) | ($1.89) | |
| Shares outstanding (diluted) | 12.7 | 12.5 | 11.0 | 9.3 | 9.3 | 8.8 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|